GGCX variants leading to biallelic deficiency to γ‐carboxylate GRP cause skin laxity in VKCFD1 patients
Autor: | Veit Hornung, Heike Singer, Klara Höning, Katrin J. Czogalla-Nitsche, Katrin Kraus, S Ghosh, Arijit Biswas, Johannes Oldenburg, Jens Müller, Francesco Forin, Matthias Watzka |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Coagulation Factor Deficiency Carboxy-Lyases In vitro toxicology Biology Phenotype Pathophysiology In vitro Pyruvate carboxylase Blood Coagulation Disorders Inherited Endocrinology Carbon-Carbon Ligases Internal medicine Mutation Matrix gla protein Genetics medicine biology.protein Humans Binding site Genetics (clinical) |
Zdroj: | Human Mutation. 43:42-55 |
ISSN: | 1098-1004 1059-7794 |
Popis: | γ-Glutamyl carboxylase (GGCX) catalyses γ-carboxylation of 15 different vitamin K dependent (VKD) proteins. Pathogenic variants in GGCX cause a rare hereditary bleeding disorder called Vitamin K dependent coagulation factor deficiency type 1 (VKCFD1). In addition to bleedings, some VKCFD1 patients develop skin laxity and skeletal dysmorphologies. However, the pathophysiological mechanisms underlying these non-haemorrhagic phenotypes remain elusive. Therefore, we analyzed the effect of 22 GGCX pathogenic variants on γ-carboxylation of six non-haemostatic VKD proteins (UCMA/GRP, MGP, BGLAP, GAS6, PRGP1, TMG4) in a GGCX-/- HEK293T cell line by a functional ELISA. We observed that biallelic deficiency to γ-carboxylate Gla-rich protein lead to the development of skin laxity. Markedly reduced level of γ-carboxylated MGP is crucial but not exclusive for causing facial dysmorphologies. Moreover, we identified the vitamin K hydroquinone binding site in GGCX in an in silico model by docking studies, which was further validated by functional assays. Variants affecting this site result into loss-of-function or severely diminished ability to γ-carboxylate VKD proteins and hence are involved in the most severe phenotypes. This genotype-phenotype analysis will help to develop new treatment options for VKCFD1 patients, where individualized therapy with γ-carboxylated VKD proteins may represent a promising strategy. |
Databáze: | OpenAIRE |
Externí odkaz: |